Skip to content
SEKISUI XenoTech DD Blog Logo

SEKISUI XenoTech Joins Fight Against Liver Disease

SEKISUI XenoTech is committed to furthering the knowledge surrounding hepatic diseases, such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), which affects one out of four people worldwide. Our Research BioBank is designed to provide diseased and normal pre-lysate tissue as well as disease-diagnosed hepatocytes for scientific investigation at a reasonable cost to the end user. Our tissue is collected with the initial intent for transplant, thus making it a perfect candidate to advance basic medical science and contribute to the development of new treatments. The pre-lysate tissue samples in SEKISUI XenoTech’s Research BioBank allow for the analysis of drug target expression and early markers of fatty liver diseases across diverse US populations. Pathologic diagnosis and donor demographics, BMI, history of diabetes and alcohol use data, along with representative microphotographs, are available for each specimen.

Learn more about Sekisui XenoTech’s Research BioBank

Learn more about:

About the Authors

Maciej Czerwinski currently serves as Director of Consulting at SEKISUI XenoTech. Maciej received his PhD from the University of Maryland at Baltimore Medical School in the Department of Pathology. He has been with SEKISUI XenoTech since 1999 and guides the development of products and services for the in vitro analysis of drug safety. Maciej designed a patented method to analyze the in vitro cytokine-mediated drug-drug interactions between biologics and small molecule drugs. Dr. Czerwinski is also the inventor of our patented CryostaX single-freeze pooled hepatocytes.
Michael Millhollen received his bachelor's degree in Visual Communications from the University of Kansas and has over 20 years of experience in marketing and communications. As Global Marketing Manager, he is dedicated to the objective of sharing SEKISUI XenoTech’s scientific expertise and knowledge with scientists around the world.

Learn more

about SEKISUI XenoTech’s Research BioBank

CTA - Services 10